Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 8/305% above fair value
$5.65−0.15 (-2.59%)
Close on Nov 17, 2026Market cap $10.88MP/E –Yield –
Bolt Biotherapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Bolt Biotherapeutics's operating income for the twelve months ending Sep 30, 2026 was -$27.79M. For fiscal 2025 it was -$36.11M. The highest annual figure on record is -$36.11M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$36.11M | – |
| FY2024 | Dec 31, 2024 | -$73.05M | – |
| FY2023 | Dec 31, 2023 | -$76.20M | – |
| FY2022 | Dec 31, 2022 | -$90.32M | – |
| FY2021 | Dec 31, 2021 | -$92.79M | – |
| FY2020 | Dec 31, 2020 | -$49.18M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$4.73M | – |
| Q2 FY2026 | Jun 30, 2026 | -$7.95M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.70M | – |
| Q2 FY2025 | Jun 30, 2025 | -$9.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$12.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.92M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.44M | – |
| Q2 FY2024 | Jun 30, 2024 | -$22.60M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$18.18M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$18.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.04M | – |
| Q3 FY2022 | Sep 30, 2022 | -$22.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.06M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.53M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.76M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.92M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.41M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.11M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.75M | – |
See a number that looks wrong?